Chapter 13 - Elena Made the Final Report Include Her Name Too
Arclight’s board commissioned a final governance report.
Elena insisted it not become a document proving Cassandra and Julian were uniquely defective people who invaded a healthy company.
Margaret Sloan agreed.
The report covered:
Adrian’s scientific dispute.
Cassandra’s mishandling of validation concerns.
Julian’s interception of escalation emails.
Blue Room access.
Northstar conflicts.
Aurelis licensing.
Weaknesses in the old IP subsidiary.
Founder-control culture.
Elena’s delayed cost reductions.
Board overreliance on informal founder relationships.
Security failures.
Patent-chain deficiencies.
It was devastating.
Also useful.
One paragraph concerning Elena read:
Management repeatedly prioritized scientific continuity over liquidity discipline and did not respond adequately to credible warnings regarding cash runway and organizational scale.
Elena stared at it.
“That sounds terrible.”
Margaret replied:
“Would you like it inaccurate instead?”
Elena smiled.
“No.”
Arclight changed governance.
No executive could simultaneously control finance and board administration.
IP transfers required independent review.
Scientific integrity disputes bypassed operating leadership and went directly to a board science committee.
Data-room access required two-person approval for material transactions.
Related-party discussions had to be disclosed before negotiations advanced.
Policies could not guarantee honesty.
They could make dishonesty harder to hide inside ordinary authority.
Cassandra started consulting independently.
Several companies refused to hire her.
One eventually did.
Not as CEO.
Commercial strategy.
She accepted.
Elena heard through mutual contacts that Cassandra had moved from Boston to New York.
She did not look her up.
Adrian retired after his advisory year.
On his final day, he handed Elena a flash drive.
She raised an eyebrow.
“Please tell me that is not another secret archive.”
“Vacation photographs.”
“Why would I want those?”
“You don’t. I wanted to see your face.”
Elena laughed.
Their friendship survived because Adrian never asked it to become something larger than it was.
Elena’s vision continued improving.
Not perfectly.
She needed corrective lenses.
Night driving remained difficult.
She stopped pretending recovery meant returning exactly to her previous body.
Arclight reached its next clinical milestone under Rebecca Chen.
Elena attended the board meeting.
Rebecca presented the data.
Elena asked two questions.
Then stopped.
Margaret leaned toward her.
“Only two?”
“I’m practicing governance.”
“It looks painful.”
“Extremely.”
The final financial reconciliation produced one last decision.
Elena’s founder shares had regained substantial value after the pharmaceutical partnership.
She could remain Arclight’s largest individual shareholder.
Or sell part of her stake and diversify.
Old Elena would never have considered selling.
Arclight was her life.
New Elena sold twelve percent of her holdings through a structured secondary transaction.
Not all.
Enough.
She used part of the proceeds to fund a small research foundation supporting early-career scientists who challenged senior investigators when data did not support the preferred conclusion.
Adrian called it “aggressively on theme.”
Elena agreed.
The rest went into investments having absolutely nothing to do with biotechnology.
May you like
She discovered there was a world outside the company.
It had been there the entire time.
